Variation in the Lipoprotein Lipase Gene Influences Exercise-induced Left Ventricular Growth

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2006 Jan 18

PMID 16416313

Citations 3

Authors

David M Flavell

Peter T E Wootton

Saul G Myerson

Michael J World

Dudley J Pennell

Steve E Humphries

Philippa J Talmud

Hugh E Montgomery

Affiliations

Soon will be listed here.

Abstract

The adult heart relies predominantly on fatty acids (FA) for energy generation, and defects in FA catabolism cause dramatic left ventricular (LV) growth in early age. Since lipoprotein lipase (LPL) is the key enzyme in plasma triglyceride catabolism and is highly expressed in the myocardium, we investigated an association between the functional LPL gene serine 447 stop (S447X) variant and exercise-induced LV growth. The S447X variant was genotyped in 146 British Army recruits undergoing a 10-week exercise programme. Over the training period, X447 allele carriers showed less LV growth than S447 homozygotes (SS, 5.8+/-0.7%; SX, 2.2+/-1.5%; P=0.03) and a decrease in systolic blood pressure (DeltaSBP: SS, 1.9+/-1.3 mmHg; SX, -5.7+/-2.2 mmHg; P=0.015). Although LPL genotype did not significantly predict LV growth with DeltaSBP in statistical modelling (LPL, P=0.14; DeltaSBP, P=0.06), regression analysis indicated that LPL S447X genotype effect on DeltaSBP accounted for only 20% of the effect on LV growth. In multivariate analysis, LPL, peroxisome-proliferator-activated receptor alpha and angiotensin-converting enzyme genotypes were independent predictors of cardiac growth. Thus, LPL S447X genotype influenced exercise-induced changes in LV mass and SBP. Change in blood pressure accounted for a proportion of LV growth. These data suggest that increased myocardial FA availability may reduce exercise-induced LV growth.

Citing Articles

Deep-targeted sequencing of endothelial nitric oxide synthase gene exons uncovers exercise intensity and ethnicity-dependent associations with post-exercise hypotension.

Pescatello L, Schifano E, Ash G, Panza G, Corso L, Chen M Physiol Rep. 2017; 5(22).

PMID: 29180482 PMC: 5704084. DOI: 10.14814/phy2.13510.

DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity.

Liu L, Shi X, Bharadwaj K, Ikeda S, Yamashita H, Yagyu H J Biol Chem. 2009; 284(52):36312-36323.

PMID: 19778901 PMC: 2794747. DOI: 10.1074/jbc.M109.049817.

Lipoprotein lipase and heart size.

Luft F J Mol Med (Berl). 2006; 84(2):109-11.

PMID: 16416314 DOI: 10.1007/s00109-005-0018-0.

References

Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World M . Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 2001; 358(9288):1155-6. DOI: 10.1016/s0140-6736(01)06273-0. View

Vaziri N, Liang K, Barton C . Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. Biochim Biophys Acta. 1999; 1436(3):577-84. DOI: 10.1016/s0005-2760(98)00170-2. View

Humphries S, Nicaud V, Margalef J, Tiret L, Talmud P . Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol. 1998; 18(4):526-34. DOI: 10.1161/01.atv.18.4.526. View

Masuzaki H, Jingami H, Matsuoka N, Nakagawa O, Ogawa Y, Mizuno M . Regulation of very-low-density lipoprotein receptor in hypertrophic rat heart. Circ Res. 1996; 78(1):8-14. DOI: 10.1161/01.res.78.1.8. View

Rupp H, Zarain-Herzberg A, Maisch B . The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002; 27(7):621-36. DOI: 10.1007/s00059-002-2428-x. View

Day I, Humphries S . Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem. 1994; 222(2):389-95. DOI: 10.1006/abio.1994.1507. View

Wittrup H, Tybjaerg-Hansen A, Nordestgaard B . Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999; 99(22):2901-7. DOI: 10.1161/01.cir.99.22.2901. View

Jamshidi Y, Montgomery H, Hense H, Myerson S, Torra I, Staels B . Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002; 105(8):950-5. DOI: 10.1161/hc0802.104535. View

Myerson S, Montgomery H, Whittingham M, Jubb M, World M, Humphries S . Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. Circulation. 2001; 103(2):226-30. DOI: 10.1161/01.cir.103.2.226. View

10.

Fatkin D, Graham R . Molecular mechanisms of inherited cardiomyopathies. Physiol Rev. 2002; 82(4):945-80. DOI: 10.1152/physrev.00012.2002. View

11.

Sack M, Harrington L, Jonassen A, Mjos O, Yellon D . Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2000; 14(1):31-9. DOI: 10.1023/a:1007887020332. View

12.

Marshall B, Tordjman K, Host H, Ensor N, Kwon G, Marshall C . Relative hypoglycemia and hyperinsulinemia in mice with heterozygous lipoprotein lipase (LPL) deficiency. Islet LPL regulates insulin secretion. J Biol Chem. 1999; 274(39):27426-32. DOI: 10.1074/jbc.274.39.27426. View

13.

Zhang H, Henderson H, Gagne S, Clee S, Miao L, Liu G . Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim Biophys Acta. 1996; 1302(2):159-66. DOI: 10.1016/0005-2760(96)00059-8. View

14.

Merkel M, Eckel R, Goldberg I . Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002; 43(12):1997-2006. DOI: 10.1194/jlr.r200015-jlr200. View

15.

Finck B, Kelly D . Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002; 34(10):1249-57. DOI: 10.1006/jmcc.2002.2061. View

16.

Allard M, Schonekess B, Henning S, English D, Lopaschuk G . Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994; 267(2 Pt 2):H742-50. DOI: 10.1152/ajpheart.1994.267.2.H742. View

17.

Allayee H, de Bruin T, Michelle Dominguez K, Cheng L, Ipp E, Cantor R . Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension. 2001; 38(4):773-8. DOI: 10.1161/hy1001.092617. View

18.

Clee S, Loubser O, Collins J, Kastelein J, Hayden M . The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet. 2001; 60(4):293-300. DOI: 10.1034/j.1399-0004.2001.600407.x. View

19.

Levy D, Anderson K, Savage D, Kannel W, Christiansen J, CASTELLI W . Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med. 1988; 108(1):7-13. DOI: 10.7326/0003-4819-108-1-7. View

20.

Koren M, Devereux R, Casale P, Savage D, LARAGH J . Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991; 114(5):345-52. DOI: 10.7326/0003-4819-114-5-345. View